S
Siel Olbrecht
Researcher at Katholieke Universiteit Leuven
Publications - 29
Citations - 1350
Siel Olbrecht is an academic researcher from Katholieke Universiteit Leuven. The author has contributed to research in topics: Medicine & Ovarian cancer. The author has an hindex of 7, co-authored 13 publications receiving 563 citations. Previous affiliations of Siel Olbrecht include Catholic University of Leuven.
Papers
More filters
Journal ArticleDOI
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
Nicoletta Colombo,Cristiana Sessa,A. du Bois,Jonathan A. Ledermann,WG McCluggage,Iain A. McNeish,P. Morice,Sandro Pignata,Isabelle Ray-Coquard,Ignace Vergote,Thaïs Baert,I. Belaroussi,A. Dashora,Siel Olbrecht,François Planchamp,Denis Querleu,Susana Banerjee,P. Blecharz,Ilan Bruchim,David Cibula,Nicole Concin,Ben Davidson,Mojgan Devouassoux-Shisheboran,Annamaria Ferrero,R.M. Glasspool,Antonio González-Martín,Viola Heinzelmann-Schwarz,Florence Joly,J. W. Kim,Frédéric Kridelka,Domenica Lorusso,Sven Mahner,Mikio Mikami,Mansoor Raza Mirza,Shibani Nicum,Dearbhaile M. O'Donnell,Patricia Pautier,Alexandros Rodolakis,Jalid Sehouli,Fatih Selcukbiricik,Naveena Singh,David S.P. Tan,Dirk Timmerman,Germana Tognon,J. van der Velden,Petronella O. Witteveen,AG Zeimet +46 more
TL;DR: The recommendations presented here are based on the best available evidence and expert agreement and are presented with a summary of evidence supporting each recommendation.
Journal ArticleDOI
A pan-cancer blueprint of the heterogeneous tumor microenvironment revealed by single-cell profiling.
Junbin Qian,Siel Olbrecht,Bram Boeckx,Hanne Vos,Damya Laoui,Emre Etlioglu,Els Wauters,Valentina Pomella,Sara Verbandt,Pieter Busschaert,Ayse Bassez,A. Franken,Marlies Vanden Bempt,Jieyi Xiong,Birgit Weynand,Yannick Van Herck,Asier Antoranz,Francesca Maria Bosisio,Bernard Thienpont,Giuseppe Floris,Ignace Vergote,Ann Smeets,Sabine Tejpar,Diether Lambrechts +23 more
TL;DR: This work profiles 233,591 single cells from patients with lung, colorectal, ovary and breast cancer and constructs a pan-cancer blueprint of stromal cell heterogeneity using different single-cell RNA and protein-based technologies, generating the first panoramic view on the shared complexity of stronal cells in different cancers.
Journal ArticleDOI
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease.
Nicoletta Colombo,Nicoletta Colombo,Cristiana Sessa,A. du Bois,Jonathan A. Ledermann,WG McCluggage,Iain A. McNeish,P. Morice,Sandro Pignata,Isabelle Ray-Coquard,Ignace Vergote,Thaïs Baert,I. Belaroussi,A. Dashora,Siel Olbrecht,François Planchamp,Denis Querleu +16 more
TL;DR: The European Society for Medical Oncology (ESMO) and European Society of Gynaecologia (ESGO) jointly developed clinically relevant and evidence-based recommendations in several selected areas in order to improve the quality of care for women with ovarian cancer.
Posted ContentDOI
A Pan-Cancer Blueprint of the Heterogeneous Tumour Microenvironment Revealed by Single-Cell Profiling
Junbin Qian,Siel Olbrecht,Bram Boeckx,Hanne Vos,Damya Laoui,Emre Etlioglu,Els Wauters,Valentina Pomella,Sara Verbandt,Pieter Busschaert,Ayse Bassez,A. Franken,Marlies Vanden Bempt,Jieyi Xiong,Birgit Weynand,Yannick Van Herck,Asier Antoranz,Francesca Maria Bosisio,Bernard Thienpont,Giuseppe Floris,Ignace Vergote,Ann Smeets,Sabine Tejpar,Diether Lambrechts +23 more
TL;DR: A first panoramic view on the shared complexity of stromal cells in different cancers is generated by providing a comprehensive blueprint through an interactive web server.
Journal ArticleDOI
Genomic signatures as predictive biomarkers of homologous recombination deficiency in ovarian cancer.
TL;DR: Optimal prediction models for treatments targeting DNA repair will need to integrate multiples of these genomic signatures and will also need to assess multiple resistance mechanisms such as genomic reversion events that partially or fully re-activate DNA repair.